Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01331
|
|||||
| Drug Name |
Bortezomib
|
|||||
| Synonyms |
179324-69-7; 69G8BD63PP; Boronic acid,; Bortezomib (PS-341); Bortezomib (Proteasome inhibitor); Bortezomib(JAN/USAN/INN); CHEMBL325041; DPBA; LPD 341; LPD-341; MLN-341; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; PROSCRIPT BORONIC ACID; Peptide boronate; Pyz-Phe-boroLeu; UNII-69G8BD63PP; VELCADE (TN); Velcade; Velcade (TN); Velcade, MG-341, PS-341, Bortezomib; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Multiple myeloma [ICD11:2A83] | Approved | [1] | |||
| Mantle cell lymphoma [ICD11:2A85.5] | Approved | [1] | ||||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H25BN4O4
|
|||||
| Canonical SMILES |
B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
|
|||||
| InChI |
InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
|
|||||
| InChIKey |
GXJABQQUPOEUTA-RDJZCZTQSA-N
|
|||||
| CAS Number |
CAS 179324-69-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 384.2 | Topological Polar Surface Area | 124 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 9 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 6 | |||
| PubChem CID | ||||||
| PubChem SID |
518755
,600019
,10276517
,11433362
,12015194
,14853748
,17137090
,17397304
,46508736
,50726119
,53787350
,56311715
,56311812
,56312401
,56313329
,56314055
,56314414
,56314469
,56314470
,57402302
,85096715
,87325438
,91611228
,99432365
,99443946
,103338073
,103963945
,104603020
,118048485
,118318599
,121360388
,124756934
,124950705
,125163741
,134340388
,135696579
,136023422
,136342479
,136367512
,136920302
,137030372
,141858114
,143497187
,144206183
,144206225
,152049125
,152239004
,152344341
,160829216
,160968549
|
|||||
| ChEBI ID |
ChEBI:52717
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Bortezomib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 2016 Apr;88:118-24. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.